期刊文献+

卡培他滨用于老年大肠癌患者术后辅助化疗的疗效观察 被引量:3

下载PDF
导出
摘要 目的:观察老年大肠癌患者术后应用卡培他滨辅助化疗的疗效及安全性。方法:对36例老年大肠癌患者术后用卡培他滨每日2500mg/m^2,Bid,第1天-14天,21天为1周期,连用6至8个周期,化疗结束后随访3年以上评定疗效。结果:36例患者术后1至5年的生存率分别为:1年94.4%,2年88.9%,3年77.8%,4年72.2%,5年69.4%。主要毒副反应为皮肤色素沉着、手足综合征、消化道反应等。结论:卡培他滨作为老年大肠癌术后辅助化疗疗效较好、不良反应小,特别适宜于年老体弱患者,值得推广应用。
机构地区 解放军
出处 《四川肿瘤防治》 2007年第4期277-278,共2页 Sichuan Journal of Cancer Control
  • 相关文献

参考文献10

  • 1潘明继,李永辉,刘景荣,范元芳,孙桂生,阮挺强,林晓丹.中西医结合治疗260例中晚期大肠癌的疗效观察[J].中医杂志,1996,37(4):218-220. 被引量:26
  • 2Benson Ⅲ AB,Schrag D,Somerfield MR,et al.American Society of clinical oncology recommendations on adjuvant chemotherapy for stage Ⅱ colon cancor[J].J Clin Oncol,2004,16(22):3408-3419.
  • 3Figueredo A,Charatte ML,Maroun J,et al.Adjuvant therapy for stage Ⅱ colon cancer:a systematic review from the cancer care ontario program in evidencebased care's gastrointestinal cancer disease site group[J].J Clin Oncol,2004,16(22):3395-3407.
  • 4Gills,Loprinzi CL,Sargent DJ,et al.Pooled analysis of fruorouracil-based adjuvant therapy for stage Ⅱ and Ⅲ colon cancer:Who benefits and by how much[J].J Clin Oncol,2004,22(10):1799-1806.
  • 5徐芳英,翟美娟,董健康,汪芬娟,金以森,朱益民,来茂德.临床病理因素在结肠癌和直肠癌预后中的不同作用[J].浙江大学学报(医学版),2006,35(3):303-310. 被引量:11
  • 6陈剑,韦军民,王在同,黄美雄.高龄大肠癌临床特点(附130例分析)[J].实用肿瘤学杂志,1997,11(2):128-129. 被引量:16
  • 7De Gramont A,Banzi M,Navarro,et al.Oxaliplation/5-Fu/LV in adjuvant colon cancer:Result of the international randomized MOSAIC trial[J].Proc Am Soc Clin Oncol,2003,22:10151.
  • 8Scheithauer W,Mckendrick J,Begbie S,et al.Oral capectiabine as an alter native to i.v.5-fluorouracil-based adjuvant therapy for colon cancer:safety results of a randomized,phase Ⅲ trial[J].Ann oncol,2003,14(12):1735-1743.
  • 9Schuellerj,Cassidy J,Dumont E,et al.Preferential activation of capecitabine in tumor following oral administration to colorectal patients[J].Cancer Chemother Pharmacol,2000,45:291-298.
  • 10Sakamoto J,Amada C,Sutomi M,et al.Efficacy of oral UFT as adjuvant chemotherapy after resection of rectal cancer:meta-analysis of 5-year results from four randmoized trials in 1815 patients[J].Proc Am Soc Clin Oncol,2003,22:1082a.

二级参考文献27

  • 1张培达,关键,冯国强.高龄大肠癌113例分析[J].中国肿瘤临床,1994,21(2):120-122. 被引量:58
  • 2陈峻青.提高胃癌及大肠癌治疗水平的几个问题[J].中华医学杂志,1995,75(8):453-454. 被引量:28
  • 3CHAU I,CUNNINGHAM D.Chemotherapy in colorectal cancer:new options and new challenges[J].Br Med Bull,2002,64(1):159-180.
  • 4Cororectal Cancer Collaborative Group.Palliative chemotherapy for advanced colorectal cancer:systematic review and meta-analysis[J].BMJ,2000,321:531-535.
  • 5NASH G M,SALTZ L B,KEMENY N E,et al.Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease[J].Annals Surg Oncol,2002,9(10):954-960.
  • 6BLUMBERG D,PATY P,PICON A,et al.Stage Ⅰ rectal cancer:identification of highrisk patients[J].J Am Coll Surg,1998,186(5):574-580.
  • 7WMEYER,AWAD A,STEINHAUSER B,et al.Prognostic importance of isolated peritu-moral lymphangiosis carcinoma in lymph-node-negative colorectal carcinoma[J].Langenbeck's Arch Surg,2001,386:124-131.
  • 8COLANGELO L A,GAPSTUR S M,GANN P H,et al.Colorectal cancer mortality and factors related to the insulin resistance symdrome[J].Cancer Epidemiol Biomarkers Prev,2002,11:385-391.
  • 9MEYERHARDT J A,CATALANO P J,HALLER D G,et al.Impact of diabetes mellitus on outcomes in patients with colon cancer[J].J Clin Oncol,2003,21(3):433-440.
  • 10MOLLER D E,FLIER J S.Insulin resistance-mechanisms,syndromes,and implications[J].N Engl J Med,1991,325(13):938-948.

共引文献50

同被引文献21

  • 1杨文东,李斌,王宝成.卡培他滨治疗对氟尿嘧啶耐药的晚期转移性结直肠癌的效果观察[J].肿瘤防治杂志,2005,12(5):383-384. 被引量:3
  • 2谢春英,娄思源,徐华.卡培他滨治疗对5-Fu耐药的晚期转移性结直肠癌的疗效[J].江西医学院学报,2005,45(5):163-164. 被引量:1
  • 3王晓华,侯梅.卡培他滨治疗大肠癌的研究进展[J].四川肿瘤防治,2006,19(1):62-64. 被引量:2
  • 4周际昌.实用肿癌内科学[M].北京:人民卫生出版社,1999:33.
  • 5De Gramont A,Banzi M,Navarro,et al.Oxaliplation/5-Fu/LV in adjuvant colon cancer:Result of the international randomined MOSAIC trial[J].Proc Am Soc Clin Oncol,2003,22:10 151.
  • 6Scheithauer W,Mckendrick J,Begbie S,et al.Oral capectabine as an alter native to i.v.5-fluorouracil-based adjuvant therapy for colon cancer:safety results of a randomized,phase Ⅲ trial[J].Ann oncol,2003,14(12):1 735-1 743.
  • 7Schuellerj,Cassidy J,Dumont E,et al.Preferential activation of capecitabine in tumor following oral administration to colorectal patients[J].Cancer Chemother Pharmacol,2000,45:291-298.
  • 8Anonymous.Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.Meta-analysis Group In Cancer[J].J Clin ncol,1998,16(1):301-308.
  • 9Van-Cutsem E,Findlay M,Osterwalder B,et al.Capecitabine,an oral fluoropyrimidine Carbamate with substantial activity in advanced colorectal cancer:results of a randomized phase Ⅱ study[J].J Clin Oncol,2000,18(6):1 337-1 345.
  • 10Anonymou S. Efficacy of intravenous continuous infusion of flu- orouracil compared with bolus administration in advanced color- ectal cancer. Meta-analysis Group In Cancer [ J ]. J Clin Oncol, 1998,16( 1 ) :301-308.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部